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Purpose: Investigate in a cross-sectional study time-dependent changes of synovial ﬂuid type II collagen
epitope C2C concentrations after knee injury and correlate to other joint injury biomarkers.
Methods: Synovial ﬂuid samples were aspirated between 0 days and 7 years after injury (n ¼ 235). Serum
was collected from 71 of the knee injured patients. Synovial ﬂuid from 8 knee-healthy subjects was used
as reference. C2C was quantiﬁed by immunoassay and structural injury was determined from magnetic
resonance images (MRI) of the injured knee acquired 1e38 days after injury (n ¼ 98). Additional joint
injury biomarker results were from earlier investigations of the same samples.
Results: Synovial ﬂuid C2C concentrations were higher in injured knees than in knees of reference
subjects from 1 day up to 7 years after injury. C2C concentrations in synovial ﬂuid and serum were
correlated (r ¼ 0.403, P < 0.001). In synovial ﬂuid from subjects early after injury (0e33 days), C2C
concentrations were correlated with cross-linked C-telopeptide of type II collagen (r ¼ 0.444, P ¼ 0.003),
ARGS-aggrecan (r ¼ 0.337, P < 0.001), osteocalcin (r ¼ 0.345, P < 0.001), osteopontin (r ¼ 0.371, P < 0.001)
and IL-8 (r ¼ 0.385, P < 0.001), but not with structural joint injury as visualized on MRI.
Conclusion: The increased levels of synovial ﬂuid C2C after injury, together with the associations seen
with several other injury-related biomarkers, suggest that an acute knee injury is associated with an
immediate and sustained local degradation of type II collagen.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Anterior cruciate ligament (ACL) injury is common in young and
middle aged active adults and is often concomitant with meniscus
and cartilage injury. It has been reported that more than 50% of the
patients with an ACL or meniscus injury develop posttraumatic
knee osteoarthritis (OA) in the following 10e20 years1. However,
the mechanisms behind the early changes in cartilage and bone
turnover and the later development of knee OA after knee injury are
not well understood.N. Kumahashi, Department of
, 89-1 Enya-cho, Izumo, Shi-
Kumahashi).
ternational. Published by Elsevier LThe articular cartilage matrix contains two main structural
components: type II collagen and aggrecan. Analysis of biomarkers
of turnover of type II collagen at the time of knee injury and during
recovery may aid our understanding of the mechanisms activated
at injury, and how they lead to the development of OA2,3.
Biochemical markers have shown potential utility in monitoring
early molecular changes in cartilage turnover after traumatic knee
joint injury4e9, and it has been reported that levels of aggrecan and
collagen fragments in synovial ﬂuid are increased several years
following joint injury9,10.
Synovial ﬂuid concentrations of collagenase generated neo-
epitope of type II collagen C2C has in animal models been associ-
ated with early OA11, rheumatoid arthritis12, and the severity of
osteochondral injury13. In humans, serum and synovial ﬂuid levels
of C2C are suggested to be associated with OA progression2,14,15, age
and gender16, and rheumatoid arthritis17. Except for one studytd. All rights reserved.
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small number of human synovial ﬂuid and serum samples over a
limited time span after injury18, there is no information on the
time-related changes of C2C after knee injury. The associations
between C2C concentrations in human synovial ﬂuid with other
biochemical or structural markers related to joint injury have to the
best of our knowledge only been addressed in one previous study,
in which synovial ﬂuid C2C concentrations were weakly correlated
with the grade and number of articular cartilage lesions15.
Further information on type II collagen proteolytic cleavage as
assessed by synovial ﬂuid C2C concentrations after knee injurymay
provide a better understanding of post-traumatic OA. The aim of
this cross-sectional study was to investigate the time-related
changes in synovial ﬂuid C2C concentrations after an acute knee
injury, and to explore the associations between this type II collagen
biomarker and other biochemical and structural markers associ-
ated with joint injury.
Materials and methods
Subjects and samples
From a cross-sectional convenience cohort, we identiﬁed 235
patients who had synovial ﬂuid aspirated from their knee 0 days to
7 years after severe knee injury (Table I). Of those,114were subjects
with acute knee injuries (veriﬁed by joint swelling and hemarth-
rosis) who did not fulﬁll the inclusion criteria of a randomized
controlled trial19,20, and 121 subjects were studied in the course of
previous cross-sectional investigations4e10,21. Eight subjects
without history of knee symptoms or knee injury, or with normal
ﬁndings on clinical examination formed a healthy reference group
and were selected to group level correspond to the age (mean,
range) and gender distribution of the knee injured subjects
(Table I). These samples have been used in previous inves-
tigations4e10,19e21. All subjects consented to take part in this study,
which was approved by the regional ethical review board at Lund
University.
Prior to the statistical analysis, subjects were stratiﬁed by time
after injury and divided into groups of 30e47 subjects each
(Table I). Synovial ﬂuid was aspirated (without lavage) from each
subject at one time point only, centrifuged at 3000 g for 10 min at
4C and the supernatants were then stored at 80C. Serum sam-
ples of venous blood, obtained at the time of synovial ﬂuid aspi-
ration, were available from 71 of the 235 knee injured patients, and
have not been used in previous studies.
Analysis of C2C concentration in synovial ﬂuid and serum
We used the C2C ELISA kit (IBEX No.60-1001-001, Montreal,
Canada) from two lots according to manufacturer guidelines.Table I
Characteristics of the study subjects. The injury groups are presented with stratiﬁcation b
were not signiﬁcantly different in males (n¼ 170) and females (n¼ 65) (P¼ 0.394), and th
age. (r ¼ 0.01, P ¼ 0.874, n ¼ 235)
Study groups n (% women)
Reference subjects 8 (25)
Injured 0e2698 days 235 (27)
Early after injury 189 (26)
0 day 33 (24)
1 day 39 (15)
2e3 days 30 (30)
4e7 days 40 (33)
8e33 days 47 (28)
Late after injury
703e2698 days (1.93e7.4 years) 46 (33)Serum samples were diluted 1:2 according to the manufacture
protocol. While the technical performance of the C2C assay for
serum has been reported in detail14,16,17, the performance for sy-
novial ﬂuid has not. Thus, an investigation of the technical perfor-
mance in synovial ﬂuid was conducted.
The high viscosity of synovial ﬂuid makes handling more difﬁ-
cult, and it has been suggested that hyaluronidase treatment im-
proves assay precision22. The dilution linearity of synovial ﬂuid
samples was therefore tested with or without hyaluronidase
treatment in ﬁve randomly selected synovial ﬂuid samples. Hyal-
uronidase treatment (bovine hyaluronidase, Sigma, #H3506) was
conducted overnight at 37C with 0.4 turbidity-reducing units/ml
synovial ﬂuid in 10 mM sodium acetate (pH 5.0) in the presence of
proteinase inhibitors (1 mM EDTA, 1 mM phenylmethylsulfonyl
ﬂuoride, 1 mM iodoacetamide, and 5 mg/ml of pepstatin A). Hyal-
uronidase treatment did not improve dilution linearity and the
synovial ﬂuid concentrations were unaffected by the treatment
(data not shown). Further analyses of C2C in synovial ﬂuid were
therefore conducted without hyaluronidase treatment.
Upper and Lower Limits Of Quantiﬁcation (ULOQ and LLOQ)were
established based on the performance of the standard curve on eight
plates by analyzing at which highest and lowest concentrations the
standards had dilution recovery between 80% and 120% and had a
coefﬁcient of variation (CV) between duplicates below 20%23.
Randomly selected knee synovial ﬂuid samples were used to
assess dilution linearity (n ¼ 6) and spiking recovery (n ¼ 23).
Approximately 26% of the synovial ﬂuid samples aspirated early
(within 33 days) after injury had hemolysis, seen as dark red color,
as compared to synovial ﬂuid without hemolysis, which were
yellowish. To investigate if hemolysis in synovial ﬂuid affects the
C2C assay, the following four spiking conditions were assessed:
synovial ﬂuid with and without hemolysis was spiked with stan-
dard followed by mixing and 30 min incubation at room temper-
ature, synovial ﬂuid without hemolysis was mixed with synovial
ﬂuid with or without hemolysis. Details on the technical perfor-
mance of the C2C ELISA in synovial ﬂuid in terms of dilution line-
arity and spiking recovery, intra- and inter-assay CV, and the
inﬂuence of thawing and freezing of samples is presented in
Supplementary data Table S1.
In the analysis of the study samples, aliquots of a control sy-
novial ﬂuid were included on all plates. No serum control samples
were used.
Other biomarkers and cytokines
A subset of synovial ﬂuid samples aspirated within 33 days after
injury were analyzed in the course of previous investigations9,19,20
for the following biomarkers: sulfated glycosaminoglycan (sGAG,
using Alcian blue precipitation), ARGS neoepitope of aggrecan
(ARGS-aggrecan from aggrecanase cleavage at theased on days after injury. The synovial ﬂuid C2C concentrations in the injury group
erewas no signiﬁcant association between the synovial ﬂuid C2C concentrations and
Age in years, median (range) Days after injury, median
22 (17e47) e
24 (13e64) 5
24 (13e64) 3
27 (14e47) 0
23 (13e42) 1
29 (16e48) 3
22 (14e64) 6
22 (15e43) 13
27 (14e53) 1484 (4.1 years)
N. Kumahashi et al. / Osteoarthritis and Cartilage 23 (2015) 1506e15121508TEGE392Y393ARGS site, in house immunoassay using the Meso Scale
Discovery (MSD) platform24), osteocalcin, secreted protein acidic
and rich in cysteine (SPARC), osteopontin (multiplex Human Bone
Panel MSD immunoassay), cartilage oligomeric matrix protein
(COMP ELISA, BioVendor R&D), interleukin (IL)-1b, IL-6, IL-8, tumor
necrosis factor (TNF)-a (multiplex Human Pro-inﬂammatory II 4-
Plex Ultra-Sensitive MSD Immunoassay) and cross-linked C-telo-
peptide of type II collagen (CTX-II, in house ELISA9).
Image acquisition and analysis
Magnetic resonance imaging (MRI; 1.5 Tesla scanner) of the
group investigated early after injury (0e33 days after injury) was
performed as described20. Brieﬂy, images were taken within a
median of 8 (range 1e38) days after injury in 98 of the 189 subjects.
MR images were assessed by an experienced musculoskeletal
radiologist for ACL tears, meniscal tears, post traumatic bone
marrow lesions (BMLs), apparent cartilage defects (evident irreg-
ularity of cartilage) and osteochondral (OC) fractures with or
without disrupted cortical bone, where fractures were considered a
proxy for the strength of impact forces applied over the articular
surfaces at the time of injury20,25. These factors were classiﬁed as
present or absent for the entire knee20.
Statistics
The Statistical Package for Social Sciences (SPSS, version 18) was
used for statistical analysis. If not stated otherwise, differences were
considered signiﬁcant if P < 0.05. The synovial ﬂuid and serum C2C,
and synovial ﬂuid COMP concentrations in the injured and reference
sampleswere normally distributed according to ShapiroeWilk tests.
Other biomarker concentrations were not normally distributed, and
to ascertain normal distribution theywere log10 transformed before
correlation analyses were conducted. ManneWhitney test was used
to compare differences in the synovial ﬂuid to serum ratio between
the early and late injury groups, for analysis of the differences in
synovial ﬂuid C2C concentrations with regard to time from injury to
aspiration, and in the comparison between centrifuging conditions.
One way ANOVA and ANCOVAwere used for the following synovial
ﬂuid C2C level comparisons: spiking recovery of sample colors, be-
tween different types of joint injuries, between all ACL injuries and
all knee injuries, between early and late stages after injury, between
males and females and between diagnostic sub-groups with regard
to structural joint damage as visualized by MRI. These comparisons
were adjusted for days between injury and synovial ﬂuid aspiration,
age and sex. Pearson partial correlation coefﬁcient (r) was used to
investigate correlations between C2C concentrations in synovial
ﬂuid and serum, between synovial ﬂuid C2C concentrations and age,
and between C2C concentrations and other biomarkers in the sy-
novial ﬂuid. These correlations were adjusted for age, sex, and time
(days) between injury and aspiration. Spearman's rank test was used
to assess the correlations between C2C concentrations in synovial
ﬂuidor serumanddays after injury. Intra-class correlation coefﬁcient
(ICC) was used to test C2C inter-batch reliability using 51 synovial
ﬂuid samples assayed on both lots.
Results
Technical performance of the C2C ELISA in synovial ﬂuid
The LLOQ and ULOQ for the C2C ELISA were 16.5 ng/ml and
500 ng/ml, respectively (Supplementary data Table S1). Within this
range, we observed good dilution linearity for synovial ﬂuid sam-
ples diluted 1:2 to 1:8 with mean recoveries between 85% and 115%
(Table S1). Analyses of synovial ﬂuid from the knee injured patientsand references were conducted at dilutions from 1:2 to 1:3, and all
samples were above LLOQ.
The intra- and inter- C2C-assay CV for our synovial ﬂuid control
sample on the ﬁrst lot was 9% and 11%, respectively (Table S1),
which is similar to CVs reported for serum14,16,17. On the second lot,
the inter-assay CV was higher (17%), and there was a shift in the
measured concentration of the synovial ﬂuid control sample with a
1.93 times lower mean concentration on the second lot. All mea-
surements on the second lot were therefore converted by a factor of
1.93. Using this conversion on the control sample on the second lot,
the inter-batch CV was 13% (compared to 32% without conversion).
Evaluation of the reliability of test-retest measurements on the two
lots using 51 synovial ﬂuid samples showed a moderate reliability
(ICC ¼ 0.61) when using converted measurements from the second
lot (without the conversion the reliability was poor with an ICC of
0.29). In the study, we used serum data measured on the ﬁrst lot,
and synovial ﬂuid data measured on both lots.
The measured C2C concentration in synovial ﬂuid was not
affected by repeated freezeethaw cycles (tested up to 10 times),
although centrifugation of synovial ﬂuid at 3000  g or 30,000  g
resulted in statistically signiﬁcantly (P < 0.001 and P ¼ 0.001,
respectively) higher C2C concentrations in the supernatant
compared to values found in neat synovial ﬂuid (Table S1).
The spiking recovery ranged between 109% and 123%, and
samples with hemolysis did not signiﬁcantly (P ¼ 0.12) differ from
samples without hemolysis (Table S1).
Concentration of C2C in synovial ﬂuid and serum
The mean (95% conﬁdence interval [CI]) synovial ﬂuid C2C
concentration was 134.6 (99.1e170.0) ng/ml for the knee healthy
reference samples. The mean (CI) C2C concentrations were 209.5
(197.6e221.5) ng/ml in synovial ﬂuid and 189.9 (177.7e202.2) ng/
ml in serum for the knee-injured patient samples. The mean (CI)
synovial ﬂuid C2C concentrations of early and late stage after injury
were 209.5 (195.2e223.8) ng/ml and 209.8 (192.8e226.8) ng/ml,
respectively, with no signiﬁcant difference between the stages
(P ¼ 0.978). Also, there was no signiﬁcant difference in synovial
ﬂuid C2C concentrations between the different types of knee in-
juries (P ¼ 0.058) or between all ACL injuries and all types of knee
injuries (P ¼ 0.423, Table S2).
The median (range) synovial ﬂuid to serum C2C concentration
ratio was 1.31 (0.55e3.56) for the entire knee injury group (n¼ 71),
with statistically signiﬁcantly (P ¼ 0.001) higher ratio for the early
after injury group (n ¼ 37) than the late after injury group (n ¼ 34),
1.46 (0.55e3.56) and 1.14 (0.63e2.33), respectively.
Time dependent change in synovial ﬂuid C2C after injury
At the day of injury (day 0), the concentration of synovial ﬂuid
C2C was not higher compared to levels in knee-healthy reference
samples (Fig. 1, Table S3). From day 1 to the interval 8e33 days after
injury the C2C levels increased, and were (except for at 2e3 days
after injury) statistically signiﬁcantly higher compared to reference
levels. This early (1e33 days after injury) increase of synovial ﬂuid
C2C levels, at most 1.7-fold higher compared to reference, was also
present 2e7 years after injury (Fig. 1, Table S3).
Correlation between C2C concentrations in synovial ﬂuid and serum,
and between synovial ﬂuid C2C and other biomarkers after knee
injury
For the knee injured patients, there was a statistically signiﬁcant
positive correlation between synovial ﬂuid and serum C2C con-
centrations (r ¼ 0.403, P < 0.001; Fig. 2).
Days after injury
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Fig. 1. Synovial ﬂuid C2C concentrations after knee injury. Samples were ordered by
time after injury and divided into groups of 30e47 subjects each according to Table I,
with day 0 plotted at 0.33 days (8 h) due to the logarithmic X-axis. The results are
expressed as means with 95% conﬁdence intervals compared with concentrations in
the reference group (dotted line and gray area). SF, synovial ﬂuid.
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were available from previous studies (early injury group, 0e33 days
after injury), synovial ﬂuid C2C concentrations were positively
correlated with concentrations of ARGS-aggrecan, sGAG, CTX-II,
osteocalcin, osteopontin, and negatively correlated with IL-8. No
statistically signiﬁcant correlations were seen in synovial ﬂuid be-
tween C2C and SPARC, IL-1b, IL-6, TNF-a, and COMP (Table II).Association between synovial ﬂuid C2C concentrations and MRI
ﬁndings
In the early after injury group, there were no statistically sig-
niﬁcant differences in synovial ﬂuid C2C concentrations between
knees with or without an ACL tear, meniscus tear, cartilage lesion or
osteochondral fracture as visualized on MRI. Nor was there aSF C2C (ng/ml)
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Fig. 2. A bivariate scatter plot of C2C concentrations in synovial ﬂuid (SF) and serum
from knee injured patients. All 71 subjects with available data (circles) are plotted. A
regression line (solid), and a line of equality (dashed) are indicated.statistically signiﬁcant difference in synovial ﬂuid C2C concentra-
tions between knees with an osteochondral fracture, with or
without disrupted cortical bone (Table III).Discussion
To the best of our knowledge, this is the ﬁrst study to investigate
human synovial ﬂuid and serum C2C concentrations in both the
early and late phases after knee injury and to examine the rela-
tionship between the synovial ﬂuid C2C and other cartilage and
bone markers, and pro-inﬂammatory cytokines. Our results show
that the C2C epitope concentrations in synovial ﬂuid from patients
with injured knees were higher than in healthy reference subjects
of comparable age from one day after the injury and several years
thereafter. In knee injured patients, the synovial ﬂuid concentra-
tions of C2C correlated positively with those in paired serum
samples and the higher synovial ﬂuid concentrations suggest a
local contribution from the injured joint. In the early phase, up to 33
days after knee injury, the synovial ﬂuid concentrations of C2C
correlated positively with concentrations in synovial ﬂuid of ARGS-
aggrecan, sGAG, CTX-II, osteocalcin, osteopontin, but negatively
with IL-8.
Synovial ﬂuid C2C levels were previously shown to correlate
positively with an increased number of high-grade cartilage lesions
detected at arthroscopy two years after ACL injury, and increased
collagen cleavage was also found in human cartilage biopsies har-
vested from the inter-condylar notch 1e8 years after ACL
injury15,26. Increased synovial ﬂuid C2C and CTX-II epitope levels
were also observed in ACL transected dog joints after three and
twelve weeks11. Our present study extends these ﬁndings and is
consistent with observations of early release into joint ﬂuid after
knee injury of cross-linked C-telopeptide fragments of type II
collagen9. Together with these earlier studies our results indicate
that the onset of MMP-mediated digestion of type II collagen in
human cartilage is initiated very early after the knee injury and
continues for several years. This process could cause an irreversible
damage to the type II collagen network in cartilage that would
allow the early increase in cartilage volume observed after joint
injury27, through an osmotically driven entry of water into the
damaged cartilage matrix. These events may represent the earliest
features leading to the development of post-injury OA28.
Interestingly, we also found that synovial ﬂuid C2C epitope
concentrations correlated to ARGS-aggrecan and sGAG in synovial
ﬂuid, which could indicate a parallel increase in both MMP andTable II
Correlation in synovial ﬂuid between C2C epitope and cytokines, cartilage and bone
markers early (0e33 days) after knee injury. Pearson partial correlation was used
with adjustments for days after injury, age and sex. Correlation was considered
signiﬁcant with correlation coefﬁcients (r) above 0.25 or below 0.25 and P-values
below 0.01 (bolded). CTX-II, cross-linked C-telopeptide of type II collagen; ARGS,
ARGS-aggrecan; sGAG, sulfated glycosaminoglycan; OCL, osteocalcin; SPARC,
secreted protein acid and rich in cysteine; OPN, osteopontin; COMP, cartilage olig-
omeric matrix protein
n r value P value
CTX-II 46 0.444 0.003
ARGS 111 0.337 <0.001
sGAG 104 0.293 0.003
COMP 111 0.012 0.898
OCL 111 0.345 <0.001
SPARC 111 0.150 0.877
OPN 111 0.371 <0.001
IL-1b 111 0.053 0.586
IL-6 111 0.014 0.880
IL-8 111 0.385 <0.001
TNF-a 111 0.025 0.801
Table III
Synovial ﬂuid C2C epitope levels in the early after injury group in relation to
structural features as visualized by MRI. MRI results were available from 98 of the
189 subjects from the early (0e33 days) injury group. ANCOVAwith adjustments for
days after injury, age and sex was used for group comparisons. C2C concentrations
are expressed as mean values (95% CI) in ng/ml. OC, osteochondral
Diagnostic groups n Mean (95% CI) and P-values
Any OC fracture 67 203.0 (175.9, 228.5)
P ¼ 0.380
No OC fracture 31 185.2 (153.6, 216.9)
P ¼ 0.630
OC fracture with disrupted
cortical bone
38 192.3 (159.0, 225.6)
P ¼ 0.580
OC fracture without disrupted
cortical bone
29 215.6 (170.8, 259.5)
ACL tear 60 207.2 (180.7, 233.7)
P ¼ 0.190
Intact ACL 38 180.4 (148.0, 212.9)
Meniscal tear 43 197.6 (163.1, 232.1)
P ¼ 0.840
No meniscal tear 55 196.2 (171.0, 221.5)
Cartilage injury 13 187.9 (122.3, 253.5)
P ¼ 0.990
No cartilage injury 85 198.2 (176.4, 220.0)
N. Kumahashi et al. / Osteoarthritis and Cartilage 23 (2015) 1506e15121510aggrecanase activity in the early phase of knee injury. However, we
found no statistically signiﬁcant correlation between C2C and
COMP in the early injury group.
Severe knee injury is associated with increased joint inﬂam-
mation19,20,29,30. However, we found no relevant positive relation-
ships between synovial ﬂuid C2C and pro-inﬂammatory cytokines
in the present study, while there was a negative correlation with
synovial ﬂuid IL-8 concentrations. These results are consistent with
the lack of correlation between pro-inﬂammatory cytokines and
ARGS-aggrecan and sGAG found in our earlier study19.
On the other hand, synovial ﬂuid C2C epitope concentrations
correlated with osteocalcin and osteopontin, which is interesting
given that 60e72% of patients with an acute knee injury have a
concomitant osteochondral fracture20,25,31. Osteocalcin is consid-
ered to be a speciﬁc marker of osteoblast activity32, and osteo-
pontin is believed to regulate matrix mineralization and to be
essential for resorption of bone by osteoclasts33,34. The origin of
synovial ﬂuid osteopontin, in the scenario of an acute knee injury, is
likely multifactorial since it is released by osteoblasts, several im-
mune cells and endothelial cells upon injury33,34. Osteopontin is
also known to have pro-inﬂammatory properties and could
contribute to prolonged inﬂammation in the injured knee joint34.
Osteocalcin, however, is bone-speciﬁc and the correlation between
synovial ﬂuid C2C and synovial ﬂuid osteocalcin may reﬂect a
simultaneous disturbance in the turnover of bone and cartilage as a
consequence of the severe impaction forces to the bone and carti-
lage matrix at the time of injury20,25,31. Such disturbance of the
cartilage to bone boundary could increase cross-talk between
cartilage and bone35.
We found no relevant relationships between synovial ﬂuid C2C-
epitope concentrations and structural injuries as visualized by MRI
in the early phase of injured knees. This is in agreement with
previous ﬁndings where no correlation was observed between
serum or urinary concentrations of C2C and radiographic features
of OA36,37. Similarly, we have shown that there was no correlation
between synovial ﬂuid concentration of aggrecan and structural
injuries as visualized by MRI20. On the other hand, correlations
between serum levels of C2C and quantitative cartilage MRI values
have been reported in subjects with symptomatic knee OA38,
indicating that C2C might be a marker for cartilage structural
processes at later stages of OA.Even though biomarkers in synovial ﬂuid may reﬂect ongoing
biological processes in the joint, the mechanisms that inﬂuence
concentrations of biomarkers in joint ﬂuid early after injury are
complex and involve both generation of biomarkers and their
removal from the synovial joint39. Our study has additional limi-
tations: for the synovial ﬂuid analysis, we had to use two different
lots of the C2C assay with moderate reliability between lots; and
due to low samples volumes, not all biomarkers were measured in
all samples.
In conclusion, we showed in this cross-sectional study an
elevated synovial ﬂuid concentration of the type II collagen C2C
epitope in the ﬁrst few days after different knee injuries, with
sustained elevated levels compared to knee healthy references for
years after trauma. This suggests that an acute knee injury is
associated with an immediate and sustained increase in the pro-
teolytic degradation of type II collagen, which is independent of
type of knee injury. Synovial ﬂuid levels of C2C were associated
with other cartilage and bone biomarkers, but not with pro-
inﬂammatory cytokines, nor with structural features of injury as
assessed by MRI.
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